AstraZeneca completed the acquisition of Fusion Pharmaceuticals for $2bn.

AstraZeneca, a pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines, completed the acquisition of Fusion Pharmaceuticals, a clinical-stage oncology company, for $2bn. "This acquisition combines Fusion's expertise and capabilities in radioconjugates, including our industry-leading radiopharmaceutical R&D, pipeline, manufacturing and actinium-225 supply chain, with AstraZeneca's leadership in small molecules and biologics engineering to develop novel radioconjugates. Expanding on our existing collaboration with AstraZeneca where we have advanced FPI-2068, an EGFR-cMET targeted radioconjugate into Phase I clinical trials, gives us a unique opportunity to accelerate the development of next-generation radioconjugates with the aim of transforming patient outcomes," John Valliant, Fusion CEO.